Home / Business and Economy / Lupin Partners for Novel Depression Drug in Canada
Lupin Partners for Novel Depression Drug in Canada
16 Feb
Summary
- Lupin and Spektus Pharma partner for DeslaFlex antidepressant.
- DeslaFlex uses proprietary Flexitab oral drug-delivery platform.
- Agreement expands Lupin's central nervous system drug portfolio.
Lupin Ltd. has entered into a significant licensing and supply agreement with Spektus Pharma to introduce DeslaFlex, a novel antidepressant, into the Canadian market. This collaboration is set to bolster Lupin's existing central nervous system (CNS) drug portfolio, offering advanced therapeutic options for individuals managing major depressive disorder. The agreement was announced on February 16, 2026.
Developed by Spektus Pharma, DeslaFlex utilizes the company's proprietary Flexitab oral drug-delivery platform, representing an innovative formulation. The partnership strategically combines Lupin's robust commercial infrastructure in Canada with Spektus's expertise in creating differentiated drug formulations. This synergy is expected to facilitate a successful market launch and establish a foundation for future product introductions.
This initiative underscores Lupin's dedication to expanding its CNS presence and contributing to Canadian healthcare solutions. Claus Jepsen, President of Global Specialty at Lupin, highlighted that DeslaFlex will provide patients and clinicians with enhanced flexibility in managing major depressive disorder, promoting personalized and patient-focused care.
For Spektus Pharma, this alliance marks a pivotal step in transitioning from drug development to commercial execution. Zarvaan Merchant, CEO of Spektus, expressed confidence that Lupin's established presence and commercial strength in Canada are ideal for realizing DeslaFlex's full potential for patients.
